We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week
Published in Renal Cell Carcinoma

Journal Scan / Research · September 22, 2020

Efficacy and Safety of Nivolumab Plus Ipilimumab vs Sunitinib in First-Line Treatment of Advanced Sarcomatoid RCC

Clinical Cancer Research

 

Additional Info

Disclosure statements are available on the authors' profiles:

Clinical Cancer Research
Efficacy and Safety of Nivolumab Plus Ipilimumab Versus Sunitinib in First-Line Treatment of Patients With Advanced Sarcomatoid Renal Cell Carcinoma
Clin. Cancer Res 2020 Sep 01;[EPub Ahead of Print], NM Tannir, S Signoretti, TK Choueiri, et al

Further Reading